Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus type 16 monovalent vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **human papillomavirus type 16 monovalent vaccine** is a prophylactic vaccine specifically formulated to induce immunity against the HPV-16 type. The vaccine contains the recombinant L1 protein of HPV-16, which self-assembles into virus-like particles (VLPs) that are non-infectious and highly immunogenic. The mechanism of action is production of neutralizing antibodies aimed at blocking HPV-16 from infecting epithelial cells, thereby preventing conditions such as cervical intraepithelial neoplasia and cervical cancer driven by this high-risk HPV type. The vaccine is designed for intramuscular administration and may be adjuvanted to enhance immunogenicity. HPV-16 monovalent vaccines have been used primarily in clinical studies and are not used as commercial products in favor of broader bivalent and multivalent vaccines.
- Other names
- HPV-16 L1 vaccineHPV16 L1 vaccineHPV 16 L1 vaccineHPV-16 monovalent vaccineHPV16 monovalent vaccineHPV 16 monovalent vaccine
02
Targets
HPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on human papillomavirus type 16 monovalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus type 16 monovalent vaccine.